Abstract 227P
Background
Even though patients with non-muscle invasive urothelial carcinoma (NMIUC) show favorable survival rates, more than a half of them relapse during follow-up, while up to 20% progress to muscle-invasive urothelial carcinoma (MIUC). As the presence of invasion confers significant prognostic and therapeutic implications for these patients, its accurate detection is imperative; this has prompted the search for biomarkers predictive of invasion, using mostly genomic analysis. In contrast to the extensive genome-based research published so far in the field of BUC, studies utilizing in-depth proteomic analysis on patient-derived tissue samples, directed toward the identification of biomarkers predictive of tumor invasion, have barely been performed.
Methods
A total of 265 radical cystectomy specimens were selected from the Department of Pathology, Seoul National University Hospital (SNUH). This cohort consisted of 39 formalin-fixed paraffin embedded (FFPE) whole tissue samples used for the in-depth proteomics analysis, besides 226 BUC cases processed and analyzed as tissue microarrays (TMAs) to validate the in-depth proteomics findings along with in vitro testsFor proteomic analysis, 31 tissue specimens, consisting of 9 IUP, 12 PUC, and 10 normal urothelium (NU), were included. Machine learning-based feature selection for candidate markers For validation of IUP, we performed immunohistochemical staining in an independent valid. ation cohort composed of 25 IUP and 16 PUC with inverted growth.
Results
Validation of TUBB6 and TGFBI as potential predictive markers of muscle-invasive urothelial carcinoma (MIUC) and prognosis determinants. tubulin beta 6 class V (TUBB6) and TGFBI mRNA high expression and TUBB6 and TGFBI protein expression levels among NMIUC (pTa/pT1) and MIUC (pT2-pT4) (SNUH). From the overall proteomic landscape, The immunohistochemical validation PYGB as a specific biomarker to distinguish between IUP and PUC with inverted growth.
Conclusions
We propose TUBB6 as a novel IHC biomarker to predict invasion and poor prognosis, also select the optimal treatment in BUC patients. We suggest PYGB as a promising immunohistochemical marker for IUP diagnosis in routine practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract